Purple Biotech LTD. (PPBT) SEC Filings — 2025
35 SEC filings for Purple Biotech LTD. (PPBT) in 2025.
Filings
- Purple Biotech Ltd. Holds Shareholder Meeting — 6-K · Dec 16, 2025
- Purple Biotech LTD. 6-K Filing — 6-K · Dec 11, 2025
- Purple Biotech Ltd. Updates Corporate Presentation — 6-K · Nov 19, 2025
- Purple Biotech LTD. 6-K Filing — 6-K · Nov 14, 2025
- Purple Biotech Hits Manufacturing Milestone for IM1240 — 6-K · Oct 29, 2025
- Purple Biotech Schedules Shareholder Meeting for December 15 — 6-K · Oct 28, 2025
- Purple Biotech Receives Nasdaq Minimum Bid Price Notification — 6-K · Oct 20, 2025
- Purple Biotech Secures $50M ATM Offering — 6-K · Sep 19, 2025
- Purple Biotech Ltd. Updates Corporate Presentation — 6-K · Sep 16, 2025
- Purple Biotech Gets European Patent Intention for NT219 Combinations — 6-K · Sep 10, 2025
- Purple Biotech Files 6-K with Warrant Forms and Press Release — 6-K · Sep 5, 2025
- Purple Biotech Announces IM1240 Data — 6-K · Sep 4, 2025
- Purple Biotech Adds Novel TROP2 Antibody to CAPTN-3 Portfolio — 6-K · Sep 3, 2025
- Purple Biotech Reports Q2 2025 Financial Results — 6-K · Aug 6, 2025
- Purple Biotech CEO Updates Shareholders on H1 2025 Progress — 6-K · Jul 23, 2025
- Purple Biotech Updates Corporate Presentation — 6-K · Jul 10, 2025
- Purple Biotech Highlights CAPTN-3 Platform at EACR 2025 — 6-K · Jun 23, 2025
- Purple Biotech Starts Phase 2 Study for NT219 in Head and Neck Cancer — 6-K · Jun 17, 2025
- Purple Biotech Reports Q1 2025 Financial Results — 6-K · May 21, 2025
- Purple Biotech Appoints New CFO — 6-K · May 12, 2025
- Purple Biotech Ltd. Updates Company Presentation — 6-K · May 6, 2025
- Purple Biotech Reports Final CM24 Pancreatic Cancer Data — 6-K · Apr 30, 2025
- Purple Biotech Reports Positive NT219 Data — 6-K · Apr 28, 2025
- Purple Biotech Ltd. Holds Annual Shareholder Meeting — 6-K · Apr 22, 2025
- Purple Biotech's NT219 Shows Promise Against Brain Metastasis — 6-K · Apr 16, 2025
- Purple Biotech Ltd. Annual Meeting Adjourned — 6-K · Apr 15, 2025
- Purple Biotech to Speak at Oncology Conference — 6-K · Apr 1, 2025
- Purple Biotech to Present at 2025 AACR Meeting — 6-K · Mar 28, 2025
- Purple Biotech Ltd. Updates Company Presentation — 6-K · Mar 18, 2025
- Purple Biotech Ltd. Files 2024 Annual Report — 20-F · Mar 10, 2025
- Purple Biotech Secures New US Patent for NT219 Combination Therapy — 6-K · Mar 5, 2025
- Purple Biotech Sets April 15 AGM Date — 6-K · Feb 28, 2025
- Purple Biotech Advances NT219 to Phase 2 for Head and Neck Cancer — 6-K · Feb 18, 2025
- Purple Biotech Partners with Mount Sinai for Antibody Platform — 6-K · Feb 3, 2025
- Purple Biotech Ltd. Files 6-K on ATM Agreement — 6-K · Jan 6, 2025